Shell Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Shell Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,797	Closed	-$225K	–	1379
2022 Q3	$225K	Sell	8,797 -2,306	-21%	-$57.9K	0.01%	958
2022 Q2	$315K	Buy	11,103 +3,796	+52%	+$120K	0.01%	956
2022 Q1	$258K	Sell	7,307 -1,099	-13%	-$36.8K	0.01%	1097
2021 Q4	$352K	Buy	8,406 +61	+0.7%	+$2.47K	0.01%	1048
2021 Q3	$410K	Sell	8,345 -360	-4%	-$17.6K	0.01%	958
2021 Q2	$363K	Buy	+8,705	New	+$337K	0.01%	1055

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Shell Asset Management's MRVI Position: Q4 2022 in Review

Shell Asset Management sold out of Maravai LifeSciences (MRVI) in Q4 2022, closing a stake of 8,797 shares — an estimated $225K sold.

Shell Asset Management first reported a position in MRVI in Q2 2021 and held it in 6 quarters. The position peaked at $410K in Q3 2021. 212 funds tracked by Wall St. Rank hold MRVI as of Q4 2022.

Shell Asset Management reported no remaining Maravai LifeSciences position as of Q4 2022 after selling out during the quarter.
Shell Asset Management sold 8,797 Maravai LifeSciences shares in Q4 2022, an estimated $225K.
Shell Asset Management first reported a position in Maravai LifeSciences in Q2 2021 and held it in 6 quarters.
Shell Asset Management's Maravai LifeSciences position peaked at $410K in Q3 2021.
212 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2022.

Based on Shell Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.